On second thoughts such is unlikely.
The background was that efficacy was already accepted so the lawyers would not ask that.
That leaves us with the potency assay data.
In person the data before and after could be readily shown in various ways to the FDA's satisfaction.
Australian newspaper article, page-119
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.01 |
Change
0.055(5.79%) |
Mkt cap ! $1.084B | |||
| Open | High | Low | Value | Volume |
| 95.5¢ | $1.03 | 95.0¢ | $2.036M | 2.053M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 50904 | $1.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.01 | 42235 | 11 |
View Market Depth
| Last trade - 10.41am 30/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |